With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
This article was originally published in The Tan Sheet
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.
You may also be interested in...
The harsh winter, weak cough/cold season and poor retail environment created “a difficult quarter for our consumer business,” which reported flat sales, says Perrigo CEO Joseph Papa. The firm also reported a continued delay in re-launching generic versions of the Mucinex expectorant line.
Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.
The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.